Drugs / PF-03758309
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00932126 | Sep 2009 → Dec 2011 | cancer | Pfizer | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-03758309 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00932126 ↗ |
| Known as | PF 3758309 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3128043 ↗ |
| Known as | PF-309 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3128043 ↗ |
| Action | Inhibit | “An Oral PAK4 Inhibitor” NCT00932126 ↗ |
| Modality | Small molecule | — CHEMBL3128043 ↗ |
| Route | Oral | “Oral PF-03758309 will be administered in capsules” NCT00932126 ↗ |
| Target | PAK4 | “An Oral PAK4 Inhibitor” NCT00932126 ↗ |